Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
- 2017
AIM: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with one or two oral glucose-lowering drugs. CONCLUSIONS: iGlarLixi consistently improved glycaemic control compared with iGlar in all baseline characteristic subgroups of patients with T2DM inadequately controlled with insulin, including difficult-to-treat subgroups of patients with long duration of diabetes, obesity and high HbA1c. Copyright This article is protected by copyright. All rights reserved. METHODS: In this exploratory analysis of LixiLan-L (N=736), efficacy outcomes were assessed within population subgroups derived from the following baseline characteristics: glycated haemoglobin (HbA1c; <8, >8% [<64, >64mmol/mol]); duration of T2DM (<10, >10years); body mass index (<30, >30kg/m2 ). Furthermore, the incidence of symptomatic hypoglycaemia with plasma glucose <3.9mmol/L (<70mg/dL) was also analysed according to the same subgroups. RESULTS: Compared with the iGlar treatment group, patients treated with iGlarLixi showed consistently greater reductions in HbA1c during the treatment period, with higher percentages of patients achieving the HbA1c target level of <7% (53mmol/mol) in all of the subpopulations tested (p<0.0001 for all), having consistent mitigation of body weight gain and with no major differences in the incidence of hypoglycaemia.
English
1462-8902
*Blood Glucose/de [Drug Effects]
*Body Weight/de [Drug Effects]
*Diabetes Mellitus, Type 2/dt [Drug Therapy]
*Hypoglycemia/ci [Chemically Induced]
*Insulin Glargine/ad [Administration & Dosage]
*Peptides/ad [Administration & Dosage]
Adult
Aged
Blood Glucose/me [Metabolism]
Body Mass Index
Diabetes Mellitus, Type 2/bl [Blood]
Diabetes Mellitus, Type 2/ep [Epidemiology]
Drug Combinations
Female
Glycated Hemoglobin A/me [Metabolism]
Humans
Hypoglycemia/ep [Epidemiology]
Male
Middle Aged
Time Factors
MedStar Health Research Institute
Journal Article
AIM: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with one or two oral glucose-lowering drugs. CONCLUSIONS: iGlarLixi consistently improved glycaemic control compared with iGlar in all baseline characteristic subgroups of patients with T2DM inadequately controlled with insulin, including difficult-to-treat subgroups of patients with long duration of diabetes, obesity and high HbA1c. Copyright This article is protected by copyright. All rights reserved. METHODS: In this exploratory analysis of LixiLan-L (N=736), efficacy outcomes were assessed within population subgroups derived from the following baseline characteristics: glycated haemoglobin (HbA1c; <8, >8% [<64, >64mmol/mol]); duration of T2DM (<10, >10years); body mass index (<30, >30kg/m2 ). Furthermore, the incidence of symptomatic hypoglycaemia with plasma glucose <3.9mmol/L (<70mg/dL) was also analysed according to the same subgroups. RESULTS: Compared with the iGlar treatment group, patients treated with iGlarLixi showed consistently greater reductions in HbA1c during the treatment period, with higher percentages of patients achieving the HbA1c target level of <7% (53mmol/mol) in all of the subpopulations tested (p<0.0001 for all), having consistent mitigation of body weight gain and with no major differences in the incidence of hypoglycaemia.
English
1462-8902
*Blood Glucose/de [Drug Effects]
*Body Weight/de [Drug Effects]
*Diabetes Mellitus, Type 2/dt [Drug Therapy]
*Hypoglycemia/ci [Chemically Induced]
*Insulin Glargine/ad [Administration & Dosage]
*Peptides/ad [Administration & Dosage]
Adult
Aged
Blood Glucose/me [Metabolism]
Body Mass Index
Diabetes Mellitus, Type 2/bl [Blood]
Diabetes Mellitus, Type 2/ep [Epidemiology]
Drug Combinations
Female
Glycated Hemoglobin A/me [Metabolism]
Humans
Hypoglycemia/ep [Epidemiology]
Male
Middle Aged
Time Factors
MedStar Health Research Institute
Journal Article